Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of LY3556050 for diabetic peripheral neuropathic pain
jRCT2031230416Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of ly3556050 in diabetic polyneuropathy (DPN) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean change from baseline for average pain intensity numeric rating scale (API-NRS). Started Nov 2023; status: active, not recruiting.
02
Drugs
ly3556050
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on jRCT2031230416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230416.